BidaskClub downgraded shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a hold rating to a sell rating in a research note published on Thursday morning.

Several other brokerages have also recently commented on HCM. MED assumed coverage on HUTCHISON CHINA/S in a research report on Monday, July 23rd. They set a positive rating for the company. Zacks Investment Research cut HUTCHISON CHINA/S from a hold rating to a sell rating in a research report on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $38.00.

HUTCHISON CHINA/S stock opened at $28.25 on Thursday. HUTCHISON CHINA/S has a 12 month low of $25.10 and a 12 month high of $42.25. The company has a quick ratio of 4.55, a current ratio of 4.67 and a debt-to-equity ratio of 0.06.

Several institutional investors and hedge funds have recently modified their holdings of the stock. OppenheimerFunds Inc. increased its position in shares of HUTCHISON CHINA/S by 76.5% during the second quarter. OppenheimerFunds Inc. now owns 2,972,947 shares of the company’s stock worth $89,604,000 after purchasing an additional 1,288,177 shares in the last quarter. Karst Peak Capital Ltd grew its holdings in HUTCHISON CHINA/S by 66.4% in the 1st quarter. Karst Peak Capital Ltd now owns 2,005,580 shares of the company’s stock valued at $59,285,000 after buying an additional 800,000 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in HUTCHISON CHINA/S by 21.9% in the 1st quarter. JPMorgan Chase & Co. now owns 1,527,742 shares of the company’s stock valued at $45,159,000 after buying an additional 274,658 shares in the last quarter. Schroder Investment Management Group grew its holdings in HUTCHISON CHINA/S by 11.0% in the 1st quarter. Schroder Investment Management Group now owns 1,281,443 shares of the company’s stock valued at $37,879,000 after buying an additional 127,279 shares in the last quarter. Finally, Bellevue Group AG grew its holdings in HUTCHISON CHINA/S by 10.0% in the 2nd quarter. Bellevue Group AG now owns 332,536 shares of the company’s stock valued at $10,023,000 after buying an additional 30,116 shares in the last quarter. Hedge funds and other institutional investors own 11.46% of the company’s stock.

HUTCHISON CHINA/S Company Profile

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.

Read More: Investing in Growth Stocks

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.